Fairvalue-Calculator Fairvalue-Calculator
EN DE

SunWay Biotech Co (1271) Fair Value & Analysis

Consumer Defensive · TW · Market cap 3.8B TWD

Price62.20 TWD
Fair Value37.48 TWD
Upside-39.7%
Quality95/100
Evidence: High Range 27.46 TWD – 41.33 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

SunWay Biotech Co (1271) currently trades at 62.20 TWD, while our model-based Fair Value estimate is 37.48 TWD — implying the stock looks roughly 39.7% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business. The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products. The company also researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus paracasei subsp. paracasei NTU 101; and related products. The company was founded in 2007 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is SunWay Biotech Co (1271) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 37.48 TWD versus a price of 62.20 TWD — about −40% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1271?
Our 21-model fair value for SunWay Biotech Co is 37.48 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 62.20 TWD.
What is the quality score of 1271?
SunWay Biotech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.